Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias

American Journal of Dermatopathology

Volumn 26, Issue 3, 2004, Pages 177-181

  Bowen, Anneli R ^a   Hanks, Adrianne N ^b   Murphy, Kelley J ^b   Florell, Scott R ^a   Grossman, Douglas ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Apoptosis; Keratinocyte; Proliferating cell nuclear antigen; Survivin; TUNEL

Indexed keywords

APOPTOSIS INHIBITOR; CYCLINE; SURVIVIN;

ACTINIC KERATOSIS; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KERATINOCYTE; NEURODERMATITIS; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SEBORRHEIC KERATOSIS; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; VERRUCA VULGARIS;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL COUNT; CELL DIVISION; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; IN SITU NICK-END LABELING; KERATINOCYTES; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROLIFERATING CELL NUCLEAR ANTIGEN; SKIN; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 2442657685     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-200406000-00001     Document Type: Article

References (33)

1. Cerroni L, Soyer HP, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol. 1995;17:7-11.
2. Collins KA, White WL. Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma. Am J Dermatopathol. 1995;17:429-438.
3. Selzer E, Schlagbauer-Wadl H, Okamoto I, et al. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res. 1998;8:197-203.
4. Leiter U, Schmid RM, Kaskel P, et al. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res. 2000;292:225-232.
5. Smoller BR, Van de Rijn M, Lebrun D, et al. bcl-2 expression reliably distinguishes trichoepitheliomas from basal cell carcinomas. Br J Dermatol. 1994;131:28-31.
6. Nakagawa K, Yamamura K, Maeda S, et al. bcl-2 expression in epidermal keratinocytic diseases. Cancer. 1994;74:1720-1724.
7. Morales-Ducret CR, van de Rijn M, LeBrun DP, et al. bcl-2 expression in primary malignancies of the skin. Arch Dermatol. 1995;131:909-912.
8. Delehedde M, Cho SH, Sarkiss M, et al. Altered expression of bcl-2 family member proteins in nonmelanoma skin cancer. Cancer. 1999;85:1514-1522.
9. Wrone-Smith T, Bergstrom J, Quevedo ME, et al. Differential expression of cell survival and cell cycle regulatory proteins in cutaneous squamoproliferative lesions. J Dermatol Sci. 1999;19:53-67.
10. Dummer R, Michie SA, Kell D, et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol. 1995;22:11-17.
11. Chrysomali E, Lozada-Nur F, Dekker NP, et al. Apoptosis in oral erythema multiforme. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83:272-280.
12. Kanitakis J, Hoyo E, Chouvet B, et al. Keratinocyte proliferation in epidermal keratinocyte disorders evaluated through PCNA/cyclin immunolabelling and AgNOR counting. Acta Derm Venereol. 1993;73:370-375.
13. Kawahira K. Immunohistochemical staining of proliferating cell nuclear antigen (PCNA) in malignant and nonmalignant skin diseases. Arch Dermatol Res. 1999;291:413-418.
14. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076-1081.
15. Florell SR, Boucher KM, Holden JA, et al. Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers. J Invest Dermatol. 2002;118:386-387.
16. Phillips P, Helm KF. Proliferating cell nuclear antigen distribution in keratoacanthoma and squamous cell carcinoma. J Cutan Pathol. 1993;20:424-428.
17. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999;23:387-388.
18. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-584.
19. Grossman D, McNiff JM, Li F, et al. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest. 1999;79:1121-1126.
20. Grossman D, Kim PJ, Blanc-Brude OP, et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest. 2001;108:991-999.
21. Allen SM, Florell SR, Hanks AN, et al. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res. 2003;63:567-572.
22. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
23. Rodriguez-Villanueva J, Greenhalgh D, Wang XJ, et al. Human keratin-1 bcl-2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation. Oncogene. 1998;16:853-863.
24. Ganguli G, Abecassis J, Wasylyk B. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO J. 2000;19:5135-5147.
25. Pena JC, Fuchs E, Thompson CB. Bcl-x expression influences keratinocyte cell survival but not terminal differentiation. Cell Growth Differ. 1997;8:619-629.
26. Mori O, Hachisuka H, Kiyokawa C, et al. Apoptosis identified by DNA fragmentation in epidermal neoplasms. J Dermatol. 1995;22:917-920.
27. Laporte M, Galand P, Fokan D, et al. Apoptosis in established and healing psoriasis. Dermatology. 2000;200:314-316.
28. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
29. Chiodino C, Cesinaro AM, Ottani D, et al. Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol. 1999;113:415-418.
30. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
31. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 1999;18:7690-7700.
32. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21:2613-2622.
33. Hoffman WH, Biade S, Zilfou JT, et al. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247-3257.